How much does a box of capmatinib cost in 2024?

Capmatinib (Capmatinib), trade name: Tabrecta, is a drug used to treat advanced or metastatic non-small cell lung cancer (N SCLC) targeted drugs, especially for patients carrying MET gene 14 exon skipping mutations. Capatinib (Capatinib) was developed by Novartis (Novartis) and launched in 20205 was approved for marketing by the U.S. Food and Drug Administration (FDA) in March, becoming the first targeted therapy drug targeting METex14 mutations.

Capmatinib (Capatinib) is not currently available in China, so patients cannot purchase it domestically and need to purchase it through overseas channels Capmatinib (Capatinib) . The price of foreign original drugs is relatively high, mostly around tens of thousands of yuan. The cheaper ones abroad are generic drugs, mainly Lao generic drugs, which cost around 3,000 yuan and have basically the same ingredients as the original drugs.

Capmatinib is a selectiveMETinhibitor. METThe tyrosine kinase receptor encoded by the gene plays a key role in cell growth, proliferation and survival. Certain mutations or abnormalities, especially 14 exon skipping mutations, lead to abnormal activation of the MET signaling pathway, thereby driving tumor growth and spread. Capatinib blocks the signaling pathway by inhibiting the activity of MET tyrosine kinase, thereby inhibiting the growth of tumor cells.

In clinical trials, capmatinib (capatinib) showed significant anti-tumor activity. In particular, in a multicenter, open-label, non-randomized study called GEOMETRY mono-1, capmatinib demonstrated encouraging efficacy in patients with METex14 mutations. Trial results show that capatinib (capatinib)has an objective response rate (ORR) of in untreated patients68%, compared with 41% in previously treated patients.

Common side effects of capmatinib include peripheral edema, nausea, vomiting, decreased appetite, and fatigue. More serious side effects may include interstitial lung disease, liver impairment, and hyperglycemia. Therefore, when treating with capmatinib (capatinib), patients need to be closely monitored by a doctor to detect and deal with possible adverse reactions in a timely manner.